Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Tech Press St. Kitts & Nevis.
Press releases published on September 11, 2025
HAProxy Dominates G2 Fall 2025 Reports
GlobeNewswire
·
September 11, 2025
NEWTON, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- HAProxy Technologies, the company behind HAProxy One, the world’s fastest application delivery and security platform, today announced another quarter of incredible success in the G2 Fall 2025 Grid® and …
Chilldyne and Carahsoft Partner to Deliver Risk-Free Liquid Cooling to Government Agencies Nationwide
GlobeNewswire
·
September 11, 2025
CARLSBAD, Calif., and RESTON, Va., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Chilldyne, Inc., a leader in negative pressure liquid cooling technology, and Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, today announced a partnership. …
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
GlobeNewswire
·
September 11, 2025
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design confirmatory trial planned for 2026 FORT …
New Engen Earns Spot on ADWEEK’s Fastest Growing Agencies List for Third Consecutive Year, Ranking Among Top Five Large Agencies in 2025
GlobeNewswire
·
September 11, 2025
SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- New Engen, a leading digital marketing agency, today announced its recognition on the 2025 ADWEEK Fastest Growing Agencies list for the third consecutive year, ranking among the top five large agencies this year. …
Longer-Term Forecasts for Litecoin are More Optimistic with Bullish Expectations Suggested
GlobeNewswire
·
September 11, 2025
PALM BEACH, Fla., Sept. 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous crypto news industry insiders are bullish for Litecoin this year and through 2031. One such observer said: “The crypto market is entering a new chapter where …
Athira Pharma Announces Reverse Stock Split
GlobeNewswire
·
September 11, 2025
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today …
LIS Technologies Inc. Appoints Former Air Force Lead for Strategy, Integration, and Requirements, Lieutenant General Hinote (Ret.) as its Executive Chair of Federal and Defense Initiatives
GlobeNewswire
·
September 11, 2025
Oak Ridge, Tennessee, Sept. 11, 2025 (GLOBE NEWSWIRE) -- LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that …
AgEagle Aerial Systems Rebrands as EagleNXT to Drive Next Phase of Growth and Innovation
GlobeNewswire
·
September 11, 2025
Rebrand reflects strategic evolution and positions EagleNXT to capture global expansion opportunities across defense, agriculture, and commercial drone markets WICHITA, Kan., Sept. 11, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS), a …
isolved Among Select Platinum Partners Integrated with Indeed’s New Talent Scout Solution
GlobeNewswire
·
September 11, 2025
CHARLOTTE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, today announced it is one of only two hand-selected partners worldwide …
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
September 11, 2025
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs …
Shoals Technologies Group Secures a New Patent for BLA Architecture, Reinforcing American Intellectual Property
GlobeNewswire
·
September 11, 2025
PORTLAND, Tenn., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (Shoals) (Nasdaq: SHLS), a global leader in electrical balance of system (EBOS) solutions for the energy transition market, announced today the issuance of its new U.S. …
VERSES® Expands Commercial Relationship with Major Global Investment Firm
GlobeNewswire
·
September 11, 2025
VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES'' or the "Company”), a cognitive computing company specializing in next-generation agentic software systems, today announced an additional …
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
GlobeNewswire
·
September 11, 2025
HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
GlobeNewswire
·
September 11, 2025
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four …
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
GlobeNewswire
·
September 11, 2025
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug- …
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
GlobeNewswire
·
September 11, 2025
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: …
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
GlobeNewswire
·
September 11, 2025
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE …
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
GlobeNewswire
·
September 11, 2025
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for …
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
GlobeNewswire
·
September 11, 2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
GlobeNewswire
·
September 11, 2025
FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for …